NAMS
NewAmsterdam PharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
NAMS Profile
Newamsterdam Pharma Company N.V.
A biotechnology company that aims to treat metabolic diseases
Pharmaceutical
10/17/2019
02/08/2021
NASDAQ Stock Exchange
68
12-31
Common stock
Gooimeer 2-35, 1411 DC Naarden, The Netherlands
--
NewAmsterdam Pharma Company N.V. was incorporated as a private limited liability company under the laws of the Netherlands on October 17, 2019 in the name of NewAmsterdam Pharma B.V. NewAmsterdam Pharma changed its name to NewAmsterdam Pharma Holding B.V. in October 2021. They are a clinical-stage biopharmaceutical company developing oral non-statins for high-risk patients with cardiovascular disease (CVD) who have elevated low-density lipoprotein cholesterol (LDL-C or LDL) residues for which existing therapies are not effective or well tolerated. There is a huge unmet need for an effective, cost-effective and convenient low-density lipoprotein reduction therapy as an adjunct to statins. Statins are currently the standard of care for patients with high cholesterol and high risk CVD. Their lead product candidate, obicetrapib, is a next-generation oral low-dose cholesterol ester transfer protein (CETP) inhibitor currently in four Phase 3 and Phase 2 b clinical trials as monotherapy and ezetimibe combination therapy for lowering LDL-C and preventing major cardiovascular adverse events (" MACE ").
